Brad McMillan is the chief investment officer at Commonwealth Financial Network®, member www.finra.org, www.sipc.org, the nation’s largest privately held independent broker/dealer–RIA. He is the primary spokesperson for Commonwealth’s investment divisions. Brad earned degrees from Dartmouth College (BA), MIT (MS in real estate development), and Boston College (MS in finance), and he holds the CFA®, CAIA, MAI, and AIF® professional certifications. Other professional qualifications include designated membership in the Appraisal Institute® (MAI), the CFA Institute, and the CAIA Association®. Brad is a frequent commentator on the financial markets, U.S. economic policy, and the global economy as a whole for a range of media, including the Wall Street Journal, CNBC, CNN International, Barron’s, and Bloomberg News. Brad has worked as a real estate developer, consultant, and lender; as an investment analyst, manager, and consultant; and as a start-up executive. He has started and run several companies and has traveled around the world.
Educated as EE, BS, MS, PhD. Worked in Corporate reseach for a large company. Life Fellow, IEEE, 9 patents. Interested in Seeking Alpha to gain access to diversified opinions on investment in my retirement.
I was a technican in telephany. I began investing for income in 1998, to prepare me for early retirement, which occured in 2003. I look at MLPs, BDCs, REITS involved in finance, senior living,and diversified very very carefully. I have a bond fund, preferreds, and dividend aristocrats through challengers. I now try to stay away from cyclical industries. I look at payout ratios, or CAD to determine the comfort level for covering dividend payouts.
Chartered Financial Analyst (CFA) (Passed Level 2)
Graduate Certificate of Mineral and Energy Economics (Curtin University)
Bachelor of Accounting (University of South Australia)
Bachelor of Commerce (Business Law ) (Curtin University)
Many industries over the years, positions range from Engineer to Investment valuation work and commercial strategy. The last several years focused on valuation of investment initiatives within Biotech, and Acquisition Integration.